A Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Malignant Pleural Effusion

NCT05330065 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

55

Enrollment

OTHER

Sponsor class

Conditions

Malignant Pleural Effusion

Interventions

DRUG: bevacizumab and camrelizumab

Sponsor

The First Affiliated Hospital of Zhengzhou University